• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Joseph H. Antin, MD


  • Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute Myeloid Leukemia.Biol Blood Marrow Transplant. 2013 Apr 2.
  • Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE.Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation.Blood. 2013 Apr 22.
  • Richardson PG, Ho VT, Giralt S, Arai S, Mineishi S, Cutler C, Antin JH, Stavitzski N, Niederwieser D, Holler E, Carreras E, Soiffer R.Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease.Ther Adv Hematol. 2012 Aug;3(4):253-65.
  • Shikari H, Antin JH, Dana R.Ocular Graft-versus-Host Disease: A Review.Surv Ophthalmol.;58(3):233-51.
  • Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP, Blazar BR, Ritz J, Soiffer RJ, Antin JH, Cutler CS.Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease.Biol Blood Marrow Transplant. 2013 May;19(5):804-11.
  • Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J.Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.Sci Transl Med. 2013 Apr 3;5(179):179ra43.
  • Gazourian L, Coronata AM, Rogers AJ, Weinhouse GL, Soiffer RJ, Antin JH, Ritz J, Ho VT, Baron RM, Washko GR.Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.Respiratory Medicine. 2013 Feb;107(2):276-83.
  • Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH.Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation.Biol Blood Marrow Transplant. 2012 Dec;18(12):1851-8.
  • Hill JA, Koo S, Guzman Suarez BB, Ho VT, Cutler C, Koreth J, Armand P, Alyea EP, Baden LR, Antin JH, Soiffer RJ, Marty FM.Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.Biol Blood Marrow Transplant. 2012 Nov;18(11):1638-48.
  • Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP.Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.J Clin Oncol. 2012 Sep 10;30(26):3202-8.
  • Kubiak DW, Koo S, Hammond SP, Armand P, Baden LR, Antin JH, Marty FM.Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.Biol Blood Marrow Transplant. 2012 Sep;18(9):1462-5.
  • Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT.A disease risk index for patients undergoing allogeneic stem cell transplantation.Blood. 2012 Jul 26;120(4):905-13.
  • Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, Horowitz MM, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P.Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.Biol Blood Marrow Transplant. 2012 Jul;18(7):1007-11.
  • Melanson SE, Stevenson K, Kim H, Antin JH, Court MH, Ho VT, Ritz J, Soiffer RJ, Kuo FC, Longtine JA, Jarolim P.Response to helsby and tingle.Am J Hematol. 2011 Apr;86(4):384.
  • Sarantopoulos S, Stevenson KE, Kim HT, Washel WS, Bhuiya NS, Cutler CS, Alyea EP, Ho VT, Soiffer RJ, Antin JH, Ritz J.Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.Blood. 2011 Feb 17;117(7):2275-83.
  • Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, Horowitz MM, Antin JH.Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010.Biol Blood Marrow Transplant. 2011 Mar;17(3):291-9.
  • Ho VT, Kim HT, Aldridge J, Liney D, Kao G, Armand P, Koreth J, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP.Use of Matched Unrelated Donors Compared with Matched Related Donors Is Associated with Lower Relapse and Superior Progression-Free Survival after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2010 Dec 27.
  • Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alyea EP, Cutler CS, Koreth J, Armand P, Ho VT, Antin JH, Soiffer RJ, Baden LR.Seroprotective Titers against 2009-H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.Biol Blood Marrow Transplant. 2010 Oct 13.
  • Melanson SE, Stevenson K, Kim H, Antin JH, Court MH, Ho VT, Ritz J, Soiffer RJ, Kuo FC, Longtine JA, Jarolim P.Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation.Am J Hematol. 2010 Dec;85(12):967-71.
  • Cutler C, Antin JH.Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.Curr Opin Hematol. 2010 Nov;17(6):500-4.
  • Porter DL, Alyea EP, Antin JH, DeLima M, Estey E, Falkenburg JH, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2010 Nov;16(11):1467-503.
  • Koreth J, Biernacki M, Aldridge J, Kim HT, Alyea EP, Armand P, Cutler C, Ho VT, Wu CJ, Antin JH, Soiffer RJ.Syngeneic Donor Hematopoietic Stem Cell Transplantation is Associated with High Rates of Engraftment Syndrome.Biol Blood Marrow Transplant. 2010 Sep 23.
  • Armand P, Kim HT, Rhodes J, Sainvil MM, Cutler C, Ho VT, Koreth J, Alyea EP, Hearsey D, Neufeld EJ, Fleming MD, Steen H, Anderson D, Kwong RY, Soiffer RJ, Antin JH.Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation.Biol Blood Marrow Transplant. 2010 Sep 17.
  • Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, Reynolds C, Liney D, Kao G, Ho V, Armand P, Koreth J, Alyea E, Dey BR, Attar E, Spitzer T, Boussiotis VA, Ritz J, Soiffer R, Antin JH, Ballen K.Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.Bone Marrow Transplant. 2010 Aug 9.
  • Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC.Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial.Biol Blood Marrow Transplant. 2010 Jul;16(7):1005-17.
  • Ballen KK, Cutler C, Yeap BY, McAfee SL, Dey BR, Attar EC, Chen YB, Haspel RL, Liney D, Koreth J, Ho V, Alyea EP, Soiffer RJ, Spitzer TR, Antin JH.Donor Derived Second Hematologic Malignancies after Cord Blood Transplantation.Biol Blood Marrow Transplant. 2010 Jul;16(7):1025-31.
  • Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf D.The outcome of full intensity and reduced intensity conditioning matched sibling or unrelated donor (URD) transplantation in adults with Philadelphia chromosome negative acute lymphoblastic leukemia (PH- ALL) in first and second complete remission (CR1 and CR2).Blood. 2010 Jul 22;116(3):366-74.
  • Antin JH.The 2010 Education Supplement on Hematopoietic Stem Cell Transplantation.Biol Blood Marrow Transplant. 2010 Jan 1;16(1):S1.
  • Cutler C, Kim HT, Ayanian S, Bradwin G, Revta C, Aldridge J, Ho V, Alyea E, Koreth J, Armand P, Soiffer R, Ritz J, Richardson PG, Antin JH.Prediction Of Veno-Occlusive Disease Using Biomarkers Of Endothelial Injury.Biol Blood Marrow Transplant. 2010 Aug;16(8):1180-5.
  • Brown JA, Stevenson K, Kim HT, Cutler C, Ballen K, McDonough S, Reynolds C, Herrera M, Liney D, Ho V, Kao G, Armand P, Koreth J, Alyea E, McAfee S, Attar E, Dey B, Spitzer T, Soiffer R, Ritz J, Antin JH, Boussiotis VA.Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.Blood. 2010 May 20;115(20):4111-9.
  • Koreth J, Aldridge J, Kim HT, Alyea EP, Cutler C, Armand P, Ritz J, Antin JH, Soiffer RJ, Ho VT.Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced Age.Biol Blood Marrow Transplant. 2010 Jun;16(6):792-800.
  • Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, Soiffer RJ, Ritz J.Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.J Clin Invest. 2010 May 3;120(5):1479-93.
  • Koreth J, Antin JH.Iron overload in hematologic malignancies and outcome of allogeneic hematopoietic stem cell transplantation.Haematologica. 2010 Mar;95(3):364-6.
  • Ofran Y, Kim HT, Brusic V, Blake L, Mandrell M, Wu CJ, Sarantopoulos S, Bellucci R, Keskin DB, Soiffer RJ, Antin JH, Ritz J.Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes.Clin Cancer Res. 2010 Mar 1;16(5):1642-51.
  • Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, Guinan E, Vogelsang G, Krishnan A, Giralt S, Revta C, Carreau NA, Iacobelli M, Carreras E, Ruutu T, Barbui T, Antin JH, Niederwieser D.Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.Biol Blood Marrow Transplant. 2010 Feb;16(2):157-68. Review.
  • Chang G, Meadows ME, Jones JA, Antin JH, Orav EJ.Substance use and survival after treatment for chronic myelogenous leukemia (CML) or myelodysplastic syndrome (MDS).Am J Drug Alcohol Abuse. 2010 Jan;36(1):1-6.
  • Storb R, Antin JH, Cutler C.Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?.Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S18-27. Review.
  • McCarroll SA, Bradner JE, Turpeinen H, Volin L, Martin PJ, Chilewski SD, Antin JH, Lee SJ, Ruutu T, Storer B, Warren EH, Zhang B, Zhao LP, Ginsburg D, Soiffer RJ, Partanen J, Hansen JA, Ritz J, Palotie A, Altshuler D.Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.Nat Genet. 2009 Dec;41(12):1341-4.
  • Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P, Cutler C, Ritz J, Antin JH, Soiffer RJ, Alyea EP.Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.Blood. 2009 Oct 29;114(18):3956-9.
  • Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn JY, Cervantes F, Copelan E, Gale R, Gratwohl A, Khoury HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, Horowitz MM, Arora M, .Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse.Biol Blood Marrow Transplant. 2009 Nov;15(11):1475-8.
  • Ho VT, Vanneman M, Kim H, Sasada T, Kang YJ, Pasek M, Cutler C, Koreth J, Alyea E, Sarantopoulos S, Antin JH, Ritz J, Canning C, Kutok J, Mihm MC, Dranoff G, Soiffer R.Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15825-30.
  • Korngold R, Antin JH.Biology and management of acute graft-versus-host disease.Cancer Treat Res. 2009;144:257-75. Review.
  • Chang G, Meadows ME, Orav EJ, Antin JH.Mental status changes after hematopoietic stem cell transplantation.Cancer. 2009 Oct 1;115(19):4625-35.
  • Chen YB, Kim HT, McDonough S, Odze RD, Yao X, Lazo-Kallanian S, Spitzer TR, Soiffer R, Antin JH, Ritz J.Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2009 Sep;15(9):1066-76.
  • Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S, .Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation.British Journal of Haematology. 2009 Jun;145(6):816-24.
  • Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, Antin JH, Soiffer RJ, Alyea EP.Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.Biol Blood Marrow Transplant. 2009 Jul;15(7):844-50.
  • Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C.Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.JAMA. 2009 Jun 10;301(22):2349-61. Review.
  • Arora M,Weisdorf DJ,Spellman SR,Haagenson MD,Klein JP,Hurley CK,Selby GB,Antin JH,Kernan NA,Kollman C,Nademanee A,McGlave P,Horowitz MM,Petersdorf EW.HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.J Clin Oncol. 2009 Apr 1;27(10):1644-52.
  • Oliansky DM,Antin JH,Bennett JM,Deeg HJ,Engelhardt C,Heptinstall KV,de Lima M,Gore SD,Potts RG,Silverman LR,Jones RB,McCarthy PL Jr,Hahn T.The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.Biol Blood Marrow Transplant. 2009 Feb;15(2):137-72. Review.
  • Sarantopoulos S,Stevenson KE,Kim HT,Cutler CS,Bhuiya NS,Schowalter M,Ho VT,Alyea EP,Koreth J,Blazar BR,Soiffer RJ,Antin JH,Ritz J.Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.Blood. 2009 Apr 16;113(16):3865-74.
  • Delaney M,Cutler CS,Haspel RL,Yeap BY,McAfee SL,Dey BR,Attar E,Kao G,Alyea EP,Koreth J,Ho VT,Saidman S,Liney D,Sese D,Soiffer RJ,Spitzer TR,Antin JH,Ballen KK.High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults.Transfusion. 2009 May;49(5):995-1002.
  • Ringden O,Pavletic SZ,Anasetti C,Barrett AJ,Wang T,Wang D,Antin JH,Di Bartolomeo P,Bolwell BJ,Bredeson C,Cairo MS,Gale RP,Gupta V,Hahn T,Hale GA,Halter J,Jagasia M,Litzow MR,Locatelli F,Marks DI,McCarthy PL,Cowan MJ,Petersdorf EW,Russell JA,Schiller GJ,Schouten H,Spellman S,Verdonck LF,Wingard JR,Horowitz MM,Arora M.The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.Blood. 2009 Mar 26;113(13):3110-8.
  • Armand P,Gannamaneni S,Kim HT,Cutler CS,Ho VT,Koreth J,Alyea EP,LaCasce AS,Jacobsen ED,Fisher DC,Brown JR,Canellos GP,Freedman AS,Soiffer RJ,Antin JH.Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.J Clin Oncol. 2008 Dec 10;26(35):5767-74.
  • Cutler C,Stevenson K,Kim HT,Richardson P,Ho VT,Linden E,Revta C,Ebert R,Warren D,Choi S,Koreth J,Armand P,Alyea E,Carter S,Horowitz M,Antin JH,Soiffer R.Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.Blood. 2008 Dec 1;112(12):4425-31.
  • Lee SJ,Kukreja M,Wang T,Giralt SA,Szer J,Arora M,Woolfrey AE,Cervantes F,Champlin RE,Gale RP,Halter J,Keating A,Marks DI,McCarthy PL,Olavarria E,Stadtmauer EA,Abecasis M,Gupta V,Khoury HJ,George B,Hale GA,Liesveld JL,Rizzieri DA,Antin JH,Bolwell BJ,Carabasi MH,Copelan E,Ilhan O,Litzow MR,Schouten HC,Zander AR,Horowitz MM,Maziarz RT.Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.Blood. 2008 Oct 15;112(8):3500-7.
  • Yanik GA,Ho VT,Levine JE,White ES,Braun T,Antin JH,Whitfield J,Custer J,Jones D,Ferrara JL,Cooke KR.The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.Blood. 2008 Oct 15;112(8):3073-81.
  • Alyea EP,Li S,Kim HT,Cutler C,Ho V,Soiffer RJ,Antin JH.Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6.
  • Armistead PM,Mohseni M,Gerwin R,Walsh EC,Iravani M,Chahardouli B,Rostami S,Zhang W,Neuberg D,Rioux J,Ghavamzadeh A,Ritz J,Antin JH,Wu CJ.Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation.Exp Hematol. 2008 Sep;36(9):1205-15.
  • Haspel RL, Kao G, Yeap BY, Cutler C, Soiffer RJ, Alyea EP, Ho VT, Koreth J, Dey BR, McAfee SL, Attar EC, Spitzer T, Antin JH, Ballen KK.Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation.Bone Marrow Transplant. 2008 Mar;41(6):523-9.
  • Armand P, Kim HT, Ho VT, Cutler CS, Koreth J, Antin JH, LaCasce AS, Jacobsen ED, Fisher DC, Brown JR, Canellos GP, Freedman AS, Soiffer RJ, Alyea EP.Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.Biol Blood Marrow Transplant. 2008 Apr;14(4):418-25.
  • Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Buchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Dohner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A.HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.Biol Blood Marrow Transplant. 2008 Feb;14(2):187-96.
  • Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ.Costs of allogeneic hematopoietic cell transplantation with high-dose regimens.Biol Blood Marrow Transplant. 2008 Feb;14(2):197-207.
  • Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J, Alyea EP, Antin JH, Soiffer RJ.A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35.
  • Treister NS, Cook EF Jr, Antin J, Lee SJ, Soiffer R, Woo SB.Clinical evaluation of oral chronic graft-versus-host disease.Biol Blood Marrow Transplant. 2008 Jan;14(1):110-5.
  • Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M.Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007.Biol Blood Marrow Transplant. 2007 Nov;13(11):1268-85.
  • Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, Antin JH, Ritz J.High levels of B-cell activating factor in patients with active chronic graft-versus-host disease.Clin Cancer Res. 2007 Oct 15;13(20):6107-14.
  • Seeley WW, Marty FM, Holmes TM, Upchurch K, Soiffer RJ, Antin JH, Baden LR, Bromfield EB.Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6.Neurology. 2007 Jul 10;69(2):156-65.
  • Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR.Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis.Blood. 2007 Jul 15;110(2):490-500.
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR.Phase I trial of parathyroid hormone to facilitate stem cell mobilization.Biol Blood Marrow Transplant. 2007 Jul;13(7):838-43.
  • Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, Alyea EP, Lee SJ.Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy.Bone Marrow Transplant. 2007 Aug;40(3):209-17.
  • Armand P, Kim HT, Deangelo DJ, Ho VT, Cutler CS, Stone RM, Ritz J, Alyea EP, Antin JH, Soiffer RJ.Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation.Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64.
  • Armand P, Antin JH.Allogeneic stem cell transplantation for aplastic anemia.Biol Blood Marrow Transplant. 2007 May;13(5):505-16. Review.
  • Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP, Soiffer RJ, Antin JH.Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation.Blood. 2007 May 15;109(10):4586-8.
  • Ballen KK, Spitzer TR, Yeap BY, McAfee S, Dey BR, Attar E, Haspel R, Kao G, Liney D, Alyea E, Lee S, Cutler C, Ho V, Soiffer R, Antin JH.Double unrelated reduced-intensity umbilical cord blood transplantation in adults.Biol Blood Marrow Transplant. 2007 Jan;13(1):82-9.
  • Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH.Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.Blood. 2007 Apr 1;109(7):3108-14.
  • Brown JR, Kim HT, Li S, Stephans K, Fisher DC, Cutler C, Ho V, Lee SJ, Milford EL, Ritz J, Antin JH, Soiffer RJ, Gribben JG, Alyea EP.Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.Biol Blood Marrow Transplant. 2006 Oct;12(10):1056-64.
  • Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ.Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55.
  • Porter DL, Antin JH.Donor leukocyte infusions in myeloid malignancies: new strategies.Best Pract Res Clin Haematol. 2006;19(4):737-55. Review.
  • Humphreys BD, Vanguri VK, Henderson J, Antin JH.Minimal-change nephrotic syndrome in a hematopoietic stem-cell transplant recipient.Nat Clin Pract Nephrol. 2006 Sep;2(9):535-9; quiz 540.
  • Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, Antin JH.Quality of life associated with acute and chronic graft-versus-host disease.Bone Marrow Transplant. 2006 Aug;38(4):305-10.
  • Marty FM, Lowry CM, Cutler CS, Campbell BJ, Fiumara K, Baden LR, Antin JH.Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2006 May;12(5):552-9.
  • Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, Klickstein LB, Levin J, Miller K, Reynolds C, Macdonell R, Pasek M, Lee SJ, Ho V, Soiffer R, Antin JH, Ritz J, Alyea E.Rituximab for steroid-refractory chronic graft-versus-host disease.Blood. 2006 Jul 15;108(2):756-62.
  • Ho VT, Kim HT, Liney D, Milford E, Gribben J, Cutler C, Lee SJ, Antin JH, Soiffer RJ, Alyea EP.HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.Bone Marrow Transplant. 2006 May;37(9):845-50.
  • Cutler C, Antin JH.Chronic graft-versus-host disease.Curr Opin Oncol. 2006 Mar;18(2):126-31. Review.
  • Wu CJ, Krishnamurti L, Kutok JL, Biernacki M, Rogers S, Zhang W, Antin JH, Ritz J.Evidence for ineffective erythropoiesis in severe sickle cell disease.Blood. 2005 Nov 15;106(10):3639-45.
  • Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E, Ho V, Lee SJ, Soiffer R, Antin JH.Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2005 Jul;11(7):551-7.
  • Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J.Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.Blood. 2005 Oct 15;106(8):2903-11.
  • Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, Horowitz MM, Soci G, , ,.Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Socit Franaise de Greffe de Molle et Thrapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) pros.Blood. 2005 Aug 15;106(4):1495-500.
  • Cutler C, Li S, Kim HT, Laglenne P, Szeto KC, Hoffmeister L, Harrison MJ, Ho V, Alyea E, Lee SJ, Soiffer R, Sonis S, Antin JH.Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.Biol Blood Marrow Transplant. 2005 May;11(5):383-8.
  • Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, Molrine DC.Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2005 Mar;11(3):213-22.
  • Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B, Kinzler KW, Lengauer C.Contribution of bone marrow-derived endothelial cells to human tumor vasculature.Nat Med. 2005 Mar;11(3):261-2.
  • Alyea EP, Kim HT, Ho VT, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ.Comparative outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients greater than fifty years of age.Blood. 2005 Feb 15;105(4):1810-4.
  • Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, Hochberg EP, Wu CJ, Alyea EP, Cutler C, Ho V, Soiffer RJ, Antin JH, Ritz J.Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission.Blood. 2005 Apr 1;105(7):2973-8.
  • Lee SJ, Loberiza FR, Antin JH, Kirkpatrick T, Prokop L, Alyea EP, Cutler C, Ho VT, Richardson PG, Schlossman RL, Fisher DC, Logan B, Soiffer RJ.Routine screening for psychosocial distress following hematopoietic stem cell transplantation.Bone Marrow Transplant. 2005 Jan;35(1):77-83.
  • Oh H, Loberiza FR Jr, Zhang MJ, Ringden O, Akiyama H, Asai T, Miyawaki S, Okamoto S, Horowitz MM, Antin JH, Bashey A, Bird JM, Carabasi MH, Fay JW, Gale RP, Giller RH, Goldman JM, Hale GA, Harris RE, Henslee-Downey J, Kolb HJ, Litzow MR, McCarthy PL, Neudorf SM, Serna DS, Socie G, Tiberghien P, Barrett AJ.Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.Blood. 2005 Feb 15;105(4):1408-16.
  • Cutler C, Antin JH.Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation.Bone Marrow Transplant. 2004 Sep;34(6):471-6. Review.
  • Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ.Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-vs.-host disease: results of a randomized trial.Blood. 2004 Sep 1;104(5):1559-64.
  • DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I, Parekkedon B, Ritz J, Antin JH, Stone RM, Soiffer RJ.Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.Clin Cancer Res. 2004 Aug 1;10(15):5065-71.
  • Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH.Safety and Efficacy of Denileukin Diftitox in Patients with Steroid Refractory Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.Blood. 2004 Aug 15;104(4):1224-6.
  • Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH.Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.Biol Blood Marrow Transplant. 2004 May;10(5):328-36.
  • Zorn E, Miklos DB, Floyd BH, Mattes-Ritz A, Guo L, Soiffer RJ, Antin JH, Ritz J.Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation.J Exp Med. 2004 Apr 19;199(8):1133-42.
  • Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Prez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM.A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.Blood. 2004 Jul 15;104(2):579-85.
  • Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J.Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy.Transfusion. 2004 Feb;44(2):253-61.
  • Spiryda LB, Laufer MR, Soiffer RJ, Antin JA.Graft-versus-host disease of the vulva and/or vagina: Diagnosis and treatment.Biol Blood Marrow Transplant. 2003 Dec;9(12):760-5.
  • Antin JH.Stem cell transplantation-harnessing of graft-versus-malignancy.Curr Opin Hematol. 2003 Nov;10(6):440-4.
  • Miklos DB, Kim HT, Zorn E, Hochberg EP, Guo L, Mattes-Ritz A, Viatte S, Soiffer RJ, Antin JH, Ritz J.Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors.Blood. 2004 Jan 1;103(1):353-9.
  • Milinkovic M, Antin JH, Hergrueter CA, Underhill CB, Sackstein R.CD44-hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD.Blood. 2004 Jan 15;103(2):740-2.
  • Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR.Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.Blood. 2003 Oct 15;102(8):2768-76.
  • Lee SJ, Loberiza FR, Rizzo JD, Soiffer RJ, Antin JH, Weeks JC.Optimistic expectations and survival after hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2003 Jun;9(6):389-96.
  • Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ.Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.Blood. 2003 Sep 1;102(5):1578-82.
  • Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ.Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation.Blood. 2003 Sep 1;102(5):1601-5.
  • Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu A, Horowitz MM, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB.Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.Blood. 2003 Aug 1;102(3):802-9.
  • Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J.Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution.Transfusion. 2003 May;43(5):614-21.
  • Alyea EP, Weller E, Fisher DC, Freedman AS, Gribben JG, Lee S, Schlossman RL, Stone RM, Friedberg J, DeAngelo D, Liney D, Windawi S, Ng A, Mauch P, Antin JH, Soiffer RJ.Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.Biol Blood Marrow Transplant. 2002;8(11):601-7.
  • Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.Biol Blood Marrow Transplant. 2002;8(11):625-32.
  • Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC.Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.Blood. 2002 Dec 15;100(13):4337-43.
  • Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL.Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.Blood. 2002 Nov 15;100(10):3479-82.
  • Hochberg EP, Miklos DB, Neuberg D, Eichner DA, McLaughlin SF, Mattes-Ritz A, Alyea EP, Antin JH, Soiffer RJ, Ritz J.A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation.Blood. 2003 Jan 1;101(1):363-9.
  • Molrine DC, Antin JH, Guinan EC, Soiffer RJ, MacDonald K, Malley R, Malinoski F, Trocciola S, Wilson M, Ambrosino DM.Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation.Blood. 2003 Feb 1;101(3):831-6.
  • DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH.Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation.Blood. 2002 Dec 15;100(13):4367-71.
  • Lee SJ, Zahrieh D, Alyea EP, Weller E, Ho VT, Antin JH, Soiffer RJ.Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs.Blood. 2002 Oct 15;100(8):2697-702.
  • Lee S, Cook EF, Soiffer R, Antin JH.Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.Biol Blood Marrow Transplant. 2002;8(8):444-52.
  • Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ.Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.Transplantation. 2002 Jul 15;74(1):49-54.
  • Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM.Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.Blood. 2002 Jul 15;100(2):406-14.
  • Loberiza FR, Rizzo JD, Bredeson CN, Antin JH, Horowitz MM, Weeks JC, Lee SJ.Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases.J Clin Oncol. 2002 Apr 15;20(8):2118-26.
  • Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, Ferrara JL.A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation.Bone Marrow Transplant. 2002 Mar;29(5):373-7.
  • Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ, LeMaistre CF, Litzow MR, Marks D, Waller EK, Matlack M, Giralt S, Horowitz MM.The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase.Blood. 2001 Dec 1;98(12):3205-11.
  • Antin JH, Childs R, Filipovich AH, Giralt S, Mackinnon S, Spitzer T, Weisdorf D.Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood an.Biol Blood Marrow Transplant. 2001;7(9):473-85.
  • Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH, Hegland J, Kamani N, Kernan NA, King R, Ratanatharathorn V, Weisdorf D, Confer DL.Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.Blood. 2001 Oct 1;98(7):2043-51.
  • Winston DJ, Antin JH, Wolff SN, Bierer BE, Small T, Miller KB, Linker C, Kaizer H, Lazarus HM, Petersen FB, Cowan MJ, Ho WG, Wingard JR, Schiller GJ, Territo MC, Jiao J, Petrarca MA, Tonetta SA.A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.Bone Marrow Transplant. 2001 Jul;28(2):187-96.
  • Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH.Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis.J Clin Oncol. 2001 Aug 15;19(16):3685-91.
  • Wheeler C, Khurshid A, Ibrahim J, Elias A, Mauch P, Ault K, Antin J.Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).Leuk Lymphoma. 2001 Feb;40(5-6):499-509.
  • Antin JH.Acute graft-versus-host disease: inflammation run amok?.J Clin Invest. 2001 Jun;107(12):1497-8.
  • Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ.Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2001;7(4):223-9.
  • Porter DL, Luger SM, Duffy KM, Stadtmauer EA, Laport G, Schuster SJ, Orloff G, Tsai D, McDaid K, Kathakali A, Leonard DG, Antin JH.Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.Biol Blood Marrow Transplant. 2001;7(4):230-8.
  • Cutler C, Antin JH.Peripheral blood stem cells for allogeneic transplantation: a review.Stem Cells. 2001;19(2):108-17.
  • Lee SJ, Fairclough D, Antin JH, Weeks JC.Discrepancies between patient and physician estimates for the success of stem cell transplantation.JAMA. 2001 Feb 28;285(8):1034-8.
  • Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.J Clin Oncol. 2001 Feb 15;19(4):1152-9.
  • Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, Zani VJ, Stone RM.A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.Blood. 2000 Apr 15;95(8):2530-5.
  • Lee SJ, Fairclough D, Parsons SK, Soiffer RJ, Fisher DC, Schlossman RL, Antin JH, Weeks JC.Recovery after stem-cell transplantation for hematologic diseases.J Clin Oncol. 2001 Jan 1;19(1):242-52.
  • Davies SM, Kollman C, Anasetti C, Antin JH, Gajewski J, Casper JT, Nademanee A, Noreen H, King R, Confer D, Kernan NA.Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program.Blood. 2000 Dec 15;96(13):4096-102.
  • Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V.Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.Blood. 2000 Sep 15;96(6):2062-8.
  • Lee SJ, Klar N, Weeks JC, Antin JH.Predicting costs of stem-cell transplantation.J Clin Oncol. 2000 Jan;18(1):64-71.
  • Porter DL, Collins RH, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH.Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.Biol Blood Marrow Transplant. 1999;5(4):253-61.
  • Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ.Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.J Clin Oncol. 1999 Feb;17(2):561-8.
  • Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH.ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation.Transfusion. 1999 Feb;39(2):179-87.
  • Benjamin RJ, Connors JM, McGurk S, Churchill WH, Antin JH.Prolonged erythroid aplasia after major ABO-mismatched transplantation for chronic myelogenous leukemia.Biol Blood Marrow Transplant. 1998;4(3):151-6.
  • Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC.The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia.Blood. 1998 Dec 1;92(11):4047-52.
  • Vance E, George S, Guinan EC, Wheeler C, Antin JH, Ambrosino DM, Molrine DC.Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation.Bone Marrow Transplant. 1998 Oct;22(8):735-41.
  • Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.Blood. 1998 Oct 1;92(7):2303-14.
  • Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC.Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.Blood. 1998 Aug 1;92(3):737-44.
  • Chang G, McGarigle C, Spitzer TR, McAfee SL, Harris F, Piercy K, Goetz MN, Antin JH.A comparison of related and unrelated marrow donors.Psychosom Med. 1998 Mar-Apr;60(2):163-7.
  • Sehn LH, Antin JH, Shulman LN, Mauch P, Elias A, Kadin ME, Wheeler C.Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation.Blood. 1998 Jan 15;91(2):717-23.
  • Ziegler TR, Bye RL, Persinger RL, Young LS, Antin JH, Wilmore DW.Effects of glutamine supplementation on circulating lymphocytes after bone marrow transplantation: a pilot study.Am J Med Sci. 1998 Jan;315(1):4-10.
  • Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, Ferrara JL, Bierer BE, Weinstein HJ, Antin JH.Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.Bone Marrow Transplant. 1997 Nov;20(9):737-43.
  • Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH.Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.Ann Intern Med. 1997 Dec 15;127(12):1080-8.
  • Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH.Guillain-Barr syndrome following allogeneic bone marrow transplantation.Neurology. 1997 Dec;49(6):1711-4.
  • Chan CY, Molrine DC, Antin JH, Wheeler C, Guinan EC, Weinstein HJ, Phillips NR, McGarigle C, Harvey S, Schnipper C, Ambrosino DM.Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT).Bone Marrow Transplant. 1997 Jul;20(1):33-8.
  • Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH.Treatment of chronic graft-versus-host disease with clofazimine.Blood. 1997 Apr 1;89(7):2298-302.
  • Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J.Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.J Clin Oncol. 1997 Feb;15(2):433-44.
  • Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JL, Antin JH.Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation.Bone Marrow Transplant. 1996 Nov;18(5):975-80.